Experimental models for therapeutic studies of transitional cell carcinoma

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3163-3171

  Gabriel, Ute ^a   Bolenz, Christian ^a   Michel, Maurice Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bladder cancer; Experimental model; Experimental therapy; In vitro; In vivo; Review; Transitional cell carcinoma

Indexed keywords

BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; EX VIVO STUDY; EXPERIMENTAL STUDY; EXPLANT; HETEROTOPIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; TISSUE CULTURE; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HELA CELLS; HUMANS; MICE; RATS; URINARY BLADDER NEOPLASMS;

EID: 35349015213     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Tyczynski JE and Parkin DM: Bladder cancer in Europe. ENCR Cancer Fact Sheets 3: 1-4, 2003.
3. Chopin DK and Gattegno B: Superficial bladder tumors. Eur Urol 42: 533-541, 2002.
4. Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR and Wu X: E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet 70: 240-245, 2006.
5. Gey GO, Coffman WD and Kubicek MT: Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer research 12: 264-265, 1952.
6. Rigby CC and Franks LM: A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 24: 746-754, 1970.
7. Kim WJ and Quan C: Genetic and epigenetic aspects of bladder cancer. J Cell Biochem 95: 24-33, 2005.
8. Raghavan D, Russell PJ and Brown JL: Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. Semin Surg Oncol 8: 279-284, 1992.
9. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL and Debenham PG: Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012-8017, 2001.
10. Nims RW, Shoemaker AP, Bauernschub MA, Rec LJ and Harbell JW: Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination. In Vitro Cell Dev Biol Anim 34: 35-39, 1998.
11. Hoffman RM: The three-dimensional question: can clinically relevant tumor drug resistance be measured in vitro? Cancer Metastasis Rev 13: 169-173, 1994.
12. Yen WC, Schmittgen T and Au JL: Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res 13: 1887-1891, 1996.
13. Fujiyama C, Jones A, Fuggle S, Bicknell R, Cranston D and Harris AL: Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer 84: 558-564, 2001.
14. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ and Southgate J: Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 76: 843-857, 1997.
15. Sabbagh W, Masters JR, Duffy PG, Herbage D and Brown RA: In vitro assessment of a collagen sponge for engineering urothelial grafts. Br J Urol 82: 888-894, 1998.
16. Kyker KD, Culkin DJ and Hurst RE: A model for 3-dimensional growth of bladder cancers to investigate cell-matrix interactions. Urol Oncol 21: 255-261, 2003.
17. Hurst RE, Kyker KD, Bonner RB, Bowditch RD and Hemstreet GP, 3rd: Matrix-dependent plasticity of the malignant phenotype of bladder cancer cells. Anticancer Res 23: 3119-3128, 2003.
18. Dozmorov MG, Kyker KD, Saban R, Knowlton N, Dozmorov I, Centola MB and Hurst RE: Analysis of the interaction of extracellular matrix and phenotype of bladder cancer cells. BMC Cancer 6: 12, 2006.
19. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R and Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60: 2290-2299, 2000.
20. Huygens A, Huyghe D, Bormans G, Verbruggen A, Kamuhabwa AR, Roskams T and de Witte PA: Accumulation and photocytotoxicity of hypericin and analogs in two- and three-dimensional cultures of transitional cell carcinoma cells. Photochem Photobiol 78: 607-614, 2003.
21. Duggan BJ, Cotter FE, Kelly JD, Hamilton PW, McCallion K, Harkin D, Gardiner T, Anderson N, Keane PF, Johnston SR and Williamson KE: Antisense Bcl-2 oligonucleotide uptake in human transitional cell carcinoma. Eur Urol 40: 685-695, 2001.
22. Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 232: 243-254, 2006.
23. Schaaf A, Sagi S, Langbein S, Trojan L, Aiken P and Michel MS: Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 22: 188-192, 2004.
24. Gazzaniga P, Silvestri I, Gradilone A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L and Agliano AM: Gemcitabine-induced apoptosis in 5637 cell line: an in vitro model for high-risk superficial bladder cancer. Anticancer Drugs 18: 179-185, 2007.
25. Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, DeVries S, Bindley C, Newton MA, Sekhon G and Waldman F: Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 8: 2227-2240, 1994.
26. Kao C, Wu SQ, Bhatthacharya M, Meisner LF and Reznikoff CA: Losses of 3p, lip, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes Cancer 4: 158-168, 1992.
27. Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, Viars C and Theodorescu D: Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 62: 6981-6989, 2002.
28. Gildea JJ, Golden WL, Harding MA and Theodorescu D: Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 27: 252-263, 2000.
29. Cristofalo VJ, Lorenzini A, Allen RG, Torres C and Tresini M: Replicative senescence: a critical review. Mech Ageing Dev 125: 827-848, 2004.
30. Zhao L, Zhang ZY and Tong TJ: Systemic aging and replicative senescence: in vivo and in vitro. Sheng Li Ke Xue Jin Zhan 31: 205-210, 2000.
31. Burgues JP, Gomez L, Pontones JL, Vera CD, Jimenez-Cruz JF and Ozonas M: A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol 51: 962-970, 2007.
32. Miller BE, Miller FR and Heppner GH: Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures. Cancer Res 45: 4200-4205, 1985.
33. Kelly JD, Williamson KE, Weir HP, McManus DT, Hamilton PW, Keane PF and Johnston SR: Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer. BJU Int 85: 911-917, 2000.
34. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
35. Schmittgen TD, Au JL, Wientjes MG, Badalament RA and Drago JR: Cultured human bladder tumors for pharmacodynamic studies. J Urol 145: 203-207, 1991.
36. Perrapato SD, Slocum HK, Huben RP, Ghosh R and Rustum Y: Assessment of human genitourinary tumors and chemosensitivity testing in 3-dimensional collagen gel culture. J Urol 143: 1041-1045, 1990.
37. Daher A, de Boer WI, Le Frere-Belda MA, Kheuang L, Abbou CC, Radvanyi F, Jaurand MC, Thiery JP, Gil Diez de Medina S and Chopin DK: Growth, differentiation and senescence of normal human urothelium in an organ-like culture. Eur Urol 45: 799-805, 2004.
38. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peakocke M and Campisi J: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
39. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
40. Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM and Reznikoff CA: Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 12: 163-174, 1998.
41. Koshida K, Egawa M, Imao T, Mizokami A, Namiki M, Endo Y and Sasaki T: In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrix. Int J Urol 12: 67-72, 2005.
42. Oyasu R: Epithelial tumours of the lower urinary tract in humans and rodents. Food Chem Toxicol 33: 747-755, 1995.
43. Oliveira PA, Colaco A, De la Cruz PL and Lopes C: Experimental bladder carcinogenesis-rodent models. Exp Oncol 28: 2-11, 2006.
44. Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja RA and Vincent PC: Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 46: 2035-2040, 1986.
45. Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D and Bohle A: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59: 2834-2837, 1999.
46. Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C and Guillemin F: A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer 102: 280-285, 2002.
47. Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA and Moore RB: A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol 172: 2018-2022, 2004.
48. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H and Lilly M: Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 173: 604-609, 2005.
49. Loskog AS, Fransson ME and Totterman TT: AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 11: 8816-8821, 2005.
50. Kuromatsu I, Matsuo K, Takamura S, Kim G, Takebe Y, Kawamura J and Yasutomi Y: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther 8: 483-490, 2001.
51. Moltedo B, Faunes F, Haussmann D, De Ioannes P, De Ioannes AE, Puente J and Becker MI: Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins. J Urol 176: 2690-2695, 2006.
52. Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU and Totterman TH: Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 39: 384-393, 2005.
53. Lim BK, Mahendran R, Lee YK and Bay BH: Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res 93: 36-41, 2002.
54. McCue PA, Gomella LG, Veltri RW, Marley GM, Miller MC and Lattime EC: Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol 155: 1128-1132, 1996.
55. Hay JH, Busuttil A, Steel CM and Duncan W: The growth and histological characteristics of a series of human bladder cancer xenografts. Radiother Oncol 7: 331-340, 1986.
56. Kovnat A, Buick RN, Connolly JG, Jewett MA, Keresteci AG and Tannock IF: Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. Cancer Res 44: 2530-2533, 1984.
57. Abe T, Tada M, Shinohara N, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi T and Nonomura K: Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. Int J Urol 13: 47-57, 2006.
58. Luo Y, Chen X, Han R, Chorev M, Dewolf WC and O'Donnell MA: Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma. J Urol 162: 1519-1526, 1999.
59. Wada Y, Gotoh A, Shirakawa T, Hamada K and Kamidono S: Gene therapy for bladder cancer using adenoviral vector. Mol Urol 5: 47-52, 2001.
60. Satoh H, Morimoto Y, Arai T, Asanuma H, Kawauchi S, Seguchi K, Kikuchi M and Murai M: Intravesical ultrasonography for tumor staging in an orthotopically implanted rat model of bladder cancer. J Urol 177: 1169-1173, 2007.
61. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I and Moore RB: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81: 638-646, 1999.
62. Soloway MS and Masters S: Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46: 1158-1163, 1980.
63. Hegele A, Dalpke A, Heeg K, Barth P, Varga Z, Hofmann R and Olbert P: Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol 26: 274-280, 2005.
64. Oshinsky GS, Chen Y, Jarrett T, Anderson AE and Weiss GH: A model of bladder tumor xenografts in the nude rat. J Urol 154: 1925-1929, 1995.
65. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB and Benedict WF: An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7: 1575-1580, 2000.
66. Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF and Grossman HB: Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol 170: 975-978, 2003.
67. Kikuchi E, Xu S, Ohori M, Matei C, Lupu M, Menendez S, Koutcher JA and Bochner BH: Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol 170: 1375-1378, 2003.
68. Wang ZG, Durand DB, Schoenberg M and Pan YT: Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model. J Urol 174: 2376-2381, 2005.
69. Luo Y, Chen X and O'Donnell MA: Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model. J Urol 172: 2414-2420, 2004.
70. Bolenz C, Wenzel M, Cao Y, Fernández M, Trojan L, Aiken P and Michel MS: A newly developed mini-endoscope as a tool for regular diagnostic evaluation of the bladder tumor growth: A new orthotopic model for transitional cell carcinoma. 58. DGU annual congress, Hamburg, Germany. DGU, 2006.
71. Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM and Benedict WF: Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther 9: 681-686, 2002.
72. Estrada CR, Salanga M, Bielenberg DR, Harrell WB, Zurakowski D, Zhu X, Palmer MR, Freeman MR and Adam RM: Behavioral profiling of human transitional cell carcinoma ex vivo. Cancer Res 66: 3078-3086, 2006.
73. El Khatib S, Didelon J, Leroux A, Bezdetnaya L, Notter D and D'Hallewin M: Kinetics, biodistribution and therapeutic efficacy of hexylester 5-aminolevulinate induced photodynamic therapy in an orthotopic rat bladder tumor model. J Urol 172: 2013-2017, 2004.
74. Chong L, Ruping Y, Jiancheng B, Guohong Y, Yougang F, Jiansong W, Xiang G, Jie H and Shusheng X: Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biol Ther 5: 394-398, 2006.
75. Soloway MS: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37: 2918-2929, 1977.
76. Summerhayes IC and Franks LM: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 62: 1017-1023, 1979.
77. Soloway MS, Martino C, Hyatt C and Marrone JC: Immunogenicity of N-[-4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer. Natl Cancer Inst Monogr: 293-300, 1978.
78. Cohen SM, Yang JP, Jacobs JB, Arai M, Fukushima S and Friedell GH: Transplantation and cell culture of rat urinary bladder carcinoma. Invest Urol 19: 136-141, 1981.
79. Fogh J: Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr, pp. 5-9, 1978.
80. Pratsinis H, Saetta A, Gagos S and Davaris P: Isolation and characterization of a novel bladder cancer cell line: inhibition by epidermal growth factor. In Vitro Cell Dev Biol Anim 34: 722-728, 1998.
81. Cattan N, Rochet N, Mazeau C, Zanghellini E, Mari B, Chauzy C, Stora de Novion H, Amiel J, Lagrange JL, Rossi B and Gioanni J: Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors. Br J Cancer 85: 1412-1417, 2001.
82. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA and Arnstein P: Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 58: 881-890, 1977.
83. Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Nishi T and Amano Y: Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 55: 3438-3443, 1995.
84. Marshall CJ, Franks LM and Carbonell AW: Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 58: 1743-1751, 1977.
85. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H and Donner J: Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11: 765-773, 1973.
86. Bruch J, Wohr G, Bruderlein S, Barbi G, Wolter H, Dixkens C, Mattfeldt T, Moller P, Paiss T, Hautmann R, Vogel W and Hameister H: Detailed marker chromosome analysis in cell line U-BLC1, established from transitional-cell carcinoma of the bladder. Int J Cancer 80: 903-910, 1999.
87. Grossman HB, Wedemeyer G, Ren L, Wilson GN and Cox B: Improved growth of human urothelial carcinoma cell cultures. J Urol 136: 953-959, 1986.